Spinal cord stimulator global market to hit $3.6B by 2027: 7 observations

Written by Megan Wood | December 18, 2017 | Print  |

The global spinal cord stimulator market is set to grow at a compound annual growth rate of 6.4 percent through 2027, according to a Future Market Insights report.

Here are seven observations:


1. Valued at $2 billion in 2017, the market will likely hit $3.57 billion by 2027.


2. Rechargeable SCS will bring in revenue of $2.43 billion by 2027.


3. Non-rechargeable SCS is anticipated to grow at a 4.6 percent CAGR through 2027.


4. Failed back surgery syndrome is the top reason for SCS use, with complex regional pain syndrome following second.


5. Ambulatory surgery centers will see the greatest growth among end-users of SCS, growing at a 6.8 percent CAGR through 2027. SCS sales in hospitals will likely bring in $627 million.


6. North America will see sales of $3 billion in the market by 2027, with the European market growing at a 6.1 percent CAGR. Eastern Europe and Japan will each see a 6 percent CAGR growth in their markets.


7. Boston Scientific, Medtronic, Abbott, Nevro, Nuvectra, Stimwave and Saluda Medical, PTY are dominant market players.


More articles on devices:
InVivo appoints Dr. Richard Toselli acting CEO, names new board chair
Ampio reports positive phase 3 clinical trial results for knee osteoarthritis therapy: 5 highlights
Medtronic, NuVasive, Stryker & more: 13 device company notes



© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months